NanoViricides, Inc.

AMEX: NNVC · Healthcare · Biotechnology

PublicHQ Shelton, CT · FairfieldCIK 0001379006Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

34D

FH 42DQ 19GM —SS 51

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$9.5M

Employees

as of 2026-08-21

Market cap

$33.3M

as of 2026-08-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$9.5M-$9.5M2025

Operating income-$9.6M-$9.6M2025

Total assets$8.8M$8.8M2025

Liabilities$1.3M$1.3M2025

Equity$7.5M$7.5M2025

Revenue trend

FY2023 – FY2025 · USD

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is NanoViricides, Inc.’s revenue?

NanoViricides, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Tenax Therapeutics, Inc.49D Noveris Health Sciences Inc.——Grace Therapeutics, Inc.48D Lite Strategy, Inc.49D High Sierra Technologies, Inc.——BeyondSpring Inc.34D

Neighbors

Fairfield →

Interactive Brokers Group, Inc.$2.4B74B Booking Holdings Inc.$26.9B79B+United Rentals, Inc.$3.7B78B+EMCOR Group, Inc.$17.0B83B+W. R. Berkley Corporation$555.8M80B+Hubbell Incorporated$5.8B83B+

Key facts

CEOAnil R. Diwan

SectorHealthcare

IndustryBiotechnology

HeadquartersShelton, CT

ExchangeAMEX: NNVC

Employees7

IPO date2005-10-26

Latest filings

8-K2026-07-30 8-K2026-07-17 8-K2026-05-21 8-K2026-05-20 10-Q2026-05-15 10-Q2026-02-17 8-K2025-11-26 10-Q2025-11-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.